AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

UK-based pharmaceutical company AstraZeneca has reported that its Phase IIIb BATURA trial of Airsupra (albuterol/budesonide) ...

Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

Asthma is the most common chronic disease of childhood and, in the latter part of the 20th century, reached epidemic proportions. Asthma is generally believed to result from gene-environment ...

In this high-risk population of children, taking nebulized ICS (budesonide inhalation suspension) after a hospitalization or ED visit for asthma was associated with a reduced risk of a repeat ...

AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...

AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...

Nearly 28 million people in the U.S. have asthma, or about one in 12 people — and depending on where you live, the condition may be more difficult to manage. The Asthma and Allergy Foundation of ...

If you have asthma, running might worsen your symptoms, but there are precautions you can take to make it safer. Typically, symptoms like wheezing, coughing, and shortness of breath begin about 15 ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...